Clinical Trial Detail

NCT ID NCT03452137
Title A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

head and neck squamous cell carcinoma

Therapies

Atezolizumab

Age Groups: senior adult

No variant requirements are available.